CMR in Myocardial Infarction with Nonobstructive Coronary Arteries

July 9, 2024 updated by: The Affiliated Hospital of Xuzhou Medical University

Prognostic Value of CMR-related Parameters in Patients with MINOCA

MINOCA is accompanied by a worse prognosis, which is related to the inability to clarify the etiology.CMR has been explicitly recommended by guidelines as an etiologic diagnostic tool for MINOCA. Although CMR-related parameters, such as strain and ECV, have been shown to be associated with prognosis in patients with myocardial infarction. However, the relationship between CMR-strain or ECV and MINOCA is unclear. The aim of this study was to investigate the characterization of CMR-strain or ECV in patients with MINOCA and the relationship with prognosis.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

387

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

We consecutively selected patients who were suspected of myocardial infarction with concomitant CAG from January 2019 to June 2024 at the Affiliated Hospital of Xuzhou Medical University. All patients completed CMR during hospitalization. hsTnT peak was above the 99th percentile and CAG less than 50% in all patients.

Description

Inclusion Criteria:

  1. Complete CMR during hospitalization;
  2. CAG results suggesting coronary stenosis of less than 50%;
  3. peak hsTnT above the 99th percentile.

Exclusion Criteria:

  • CMR image sequences are missing or of poor quality.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Primary endpoint events included any cause, non-fatal infarction, stroke, or cardiac readmission.
Time Frame: All patients were followed until June 30, 2024
All patients were followed until June 30, 2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Affiliated Hospital of Xuzhou Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2019

Primary Completion (Actual)

June 30, 2024

Study Completion (Actual)

July 9, 2024

Study Registration Dates

First Submitted

July 9, 2024

First Submitted That Met QC Criteria

July 9, 2024

First Posted (Actual)

July 16, 2024

Study Record Updates

Last Update Posted (Actual)

July 16, 2024

Last Update Submitted That Met QC Criteria

July 9, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CMR in MINOCA

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Considering the patient's privacy and the next steps in our research program

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiac Magnetic Resonance

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe